A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy And Safety Trial Of Bapineuzumab (Aab-001, Eln115727) In Subjects With Mild to Moderate Alzheimer Disease Who Are Apolipoprotein E 4 Non-carriers
This is a study to evaluate the efficacy and safety of multiple doses of bapineuzumab in patients with mild to moderate Alzheimer Disease. Patients will receive either bapineuzumab or placebo. Each patient's participation will last approximately 1.5 years.
Inclusion Criteria:
Exclusion Criteria:
Loma Linda, California 92354, United States
Columbus, Georgia 31909, United States
Lawerenceville, Georgia 30045, United States
Wichitia, Kansas 67205, United States
Philadelphia, Pennsylvania 19104, United States
Charleston, South Carolina 29425, United States
Charleston, South Carolina 29425, United States
Charlottesville, Virginia 22908, United States
West Heidelberg, Victoria 3081, Australia
Adelaide SA, 5000, Australia
North York, Ontario M6M 3Z5, Canada
Nantes - Saint Herblain, 44093, France
Gunma, 371-0014, Japan
Gunma, 371-8511, Japan
Gunma, 375-0017, Japan
Krakow, Poland 31-531, Poland
Saint Petersburg, 190103, Russia
Saint Petersburg, 192019, Russia
Saint Petersburg, 192019, Russia
Panorama, Western Cape 7505, South Africa
Seongnam-si, Gyeonggi-do 463-707, South Korea
Thonex-Geneva, CH-1226, Switzerland